Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin

J F Connelly1

  • 1North Carolina Baptist Hospital, Winston-Salem 27157.

The Annals of Pharmacotherapy
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Vigabatrin, a new gamma-aminobutyric acid transaminase (GABA-T) inhibitor, shows effectiveness in treating refractory complex partial seizures in adults and partial seizures in children. Its favorable side-effect profile and limited drug interactions suggest potential advantages over current anticonvulsants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperammonaemia due to ornithine transcarbamylase deficiency.

Archives of disease in childhood·2010
Same author

Suxamethonium-induced hyperkalaemia 6 weeks after chemoradiotherapy in a patient with rectal carcinoma.

British journal of anaesthesia·2007
Same author

Newborn screening for congenital hypothyroidism, Victoria, Australia, 1977-1997. Part 1: The screening programme, demography, baseline perinatal data and diagnostic classification.

Journal of pediatric endocrinology & metabolism : JPEM·2002
Same author

Newborn screening for congenital hypothyroidism, Victoria, Australia, 1977-1997. Part 2: Treatment, progress and outcome.

Journal of pediatric endocrinology & metabolism : JPEM·2002
Same author

Publication rates of abstracts from two pharmacy meetings.

The Annals of pharmacotherapy·2000
Same author

Distribution plan for immune globulin intravenous during a shortage.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Area of Science:

  • Neurology
  • Pharmacology
  • Epilepsy Treatment

Background:

  • Refractory epilepsy poses a significant challenge in clinical practice.
  • Existing antiepileptic drugs (AEDs) have limitations in efficacy and tolerability.
  • Novel therapeutic agents are needed for patients with difficult-to-treat seizures.

Purpose of the Study:

  • To review the clinical use of vigabatrin, a novel gamma-aminobutyric acid transaminase (GABA-T) inhibitor.
  • To evaluate the efficacy and safety of vigabatrin in treating refractory epilepsy.
  • To provide an overview of pharmacokinetic data, neuropathology, adverse effects, and drug interactions.

Main Methods:

  • A comprehensive MEDLINE search was conducted for English-language literature up to March 1992.

Related Experiment Videos

  • Included were clinical trials, reviews, abstracts, and conference proceedings on vigabatrin and anticonvulsants.
  • Twenty-one clinical trials and eight pharmacokinetic studies were reviewed, alongside selected studies on chemistry, pharmacology, and adverse effects.

    • Main Results:

    • Vigabatrin selectively and irreversibly inhibits GABA-T, increasing GABA levels and potentially decreasing excitatory amino acids.
    • It is well absorbed, not protein-bound, and eliminated by glomerular filtration, with a short half-life allowing once or twice daily dosing.
    • Clinical trials indicate efficacy in refractory complex partial seizures (approx. 50% reduction in seizure frequency in 50% of adults) and promising results in children, including infantile spasms.

    Conclusions:

    • Vigabatrin demonstrates efficacy in treating refractory complex partial seizures in adults and partial seizures in children.
    • Its relatively benign adverse-effect profile and few drug interactions may offer advantages over existing anticonvulsants.
    • Further definitive conclusions await the results of ongoing Phase II and Phase III trials.